| Year |
Citation |
Score |
| 2001 |
Boehm J, He Y, Greiner A, Staudt L, Wirth T. Regulation of BOB.1/OBF.1 stability by SIAH. The Embo Journal. 20: 4153-62. PMID 11483518 DOI: 10.1093/Emboj/20.15.4153 |
0.418 |
|
| 2000 |
Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity. 13: 199-212. PMID 10981963 DOI: 10.1016/S1074-7613(00)00020-0 |
0.42 |
|
| 1996 |
Seyfert VL, Allman D, He Y, Staudt LM. Transcriptional repression by the proto-oncogene BCL-6. Oncogene. 12: 2331-42. PMID 8649773 |
0.431 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2003 |
Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, He Y, Li Y, Ray PE, Gutkind JS. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell. 3: 23-36. PMID 12559173 DOI: 10.1016/S1535-6108(02)00237-4 |
0.272 |
|
| 2018 |
Jacquemont S, Pacini L, Jønch AE, Cencelli G, Rozenberg I, He Y, D'Andrea L, Pedini G, Eldeeb M, Willemsen R, Gasparini F, Tassone F, Hagerman R, Gomez-Mancilla B, Bagni C. Protein synthesis levels are increased in a subset of individuals with Fragile X syndrome. Human Molecular Genetics. PMID 29590342 DOI: 10.1093/hmg/ddy099 |
0.209 |
|
| 2011 |
Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, Ramos FJ, Cornish K, He Y, Paulding C, Neri G, Chen F, Hadjikhani N, Martinet D, Meyer J, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Science Translational Medicine. 3: 64ra1. PMID 21209411 DOI: 10.1126/Scitranslmed.3001708 |
0.174 |
|
| 2016 |
Brasa S, Mueller A, Jacquemont S, Hahne F, Rozenberg I, Peters T, He Y, McCormack C, Gasparini F, Chibout SD, Grenet O, Moggs J, Gomez-Mancilla B, Terranova R. Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome. Clinical Epigenetics. 8: 15. PMID 26855684 DOI: 10.1186/s13148-016-0181-x |
0.167 |
|
| 2009 |
Lane RM, He Y. Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE epsilon 4, and hyperhomocysteinemia in neurodegenerative dementias. Medical Hypotheses. 73: 230-50. PMID 19359103 DOI: 10.1016/j.mehy.2009.01.050 |
0.166 |
|
| 2018 |
Jacquemont S, Pacini L, Jønch AE, Cencelli G, Rozenberg I, He Y, D'Andrea L, Pedini G, Eldeeb M, Willemsen R, Gasparini F, Tassone F, Hagerman R, Gomez-Mancilla B, Bagni C. Protein synthesis levels are increased in a subset of individuals with fragile X syndrome. Human Molecular Genetics. PMID 30107584 DOI: 10.1093/Hmg/Ddy291 |
0.158 |
|
| 2022 |
Svensson EC, Madar A, Campbell CD, He Y, Sultan M, Healey ML, Xu H, D'Aco K, Fernandez A, Wache-Mainier C, Libby P, Ridker PM, Beste MT, Basson CT. TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial. Jama Cardiology. PMID 35385050 DOI: 10.1001/jamacardio.2022.0386 |
0.112 |
|
| 2024 |
Donnenfeld E, Baudouin C, Galor A, Weissgerber G, He Y, Perez VL. Pharmacogenomic Analysis of Response to Topical Tumor Necrosis Factor α Antagonist Licaminlimab (OCS-02) in Dry Eye Disease. Cornea. PMID 38416549 DOI: 10.1097/ICO.0000000000003510 |
0.074 |
|
| 2013 |
Lane RM, He Y. Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: e1-73. PMID 22402324 DOI: 10.1016/j.jalz.2010.12.005 |
0.07 |
|
| 2007 |
Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. The Lancet. Neurology. 6: 501-12. PMID 17509485 DOI: 10.1016/S1474-4422(07)70109-6 |
0.057 |
|
| 2009 |
Lane R, He Y, Morris C, Leverenz JB, Emre M, Ballard C. BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 392-400. PMID 19006190 DOI: 10.1002/Mds.22357 |
0.053 |
|
| 2006 |
Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, Lane R. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Current Medical Research and Opinion. 22: 483-94. PMID 16574032 DOI: 10.1185/030079906X89685 |
0.051 |
|
| 2006 |
Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, Rapatz G, Nagel J, Lane R. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenetics and Genomics. 16: 771-4. PMID 17047484 DOI: 10.1097/01.fpc.0000220573.05714.ac |
0.045 |
|
| 2008 |
Lane R, Feldman HH, Meyer J, He Y, Ferris SH, Nordberg A, Darreh-Shori T, Soininen H, Pirttilä T, Farlow MR, Sfikas N, Ballard C, Greig NH. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenetics and Genomics. 18: 289-98. PMID 18334913 DOI: 10.1097/Fpc.0B013E3282F63F29 |
0.041 |
|
| 2018 |
Stacy R, Huttner K, Watts J, Peace J, Wirta D, Walters T, Sall K, Seaman J, Ni X, Prasanna G, Mogi M, Adams C, Yan JH, Wald M, He Y, et al. A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma. American Journal of Ophthalmology. PMID 29802818 DOI: 10.1016/J.Ajo.2018.05.015 |
0.038 |
|
| 2023 |
Burstedt M, Whelan JH, Green JS, Holopigian K, Spera C, Greco E, Deslandes JY, Wald M, Grosskreutz C, Ni X, Normand G, Maker M, Charil A, Rosol M, He Y, et al. Retinal Dystrophy Associated With RLBP1 Retinitis Pigmentosa: A Five-Year Prospective Natural History Study. Investigative Ophthalmology & Visual Science. 64: 42. PMID 37883093 DOI: 10.1167/iovs.64.13.42 |
0.036 |
|
| 2010 |
Lane R, He Y. P1-085: Butyrylcholinesterase genotype and gender influence phenotype in early Alzheimer's disease Alzheimer's & Dementia. 6: S198-S199. DOI: 10.1016/j.jalz.2010.05.633 |
0.035 |
|
| 2005 |
HE Y, BALCH A, CAMPESTRINI J, RIVERE G, SERRA D, PRASAD P, LIGUEROSSAYLAN M. Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with type 2 diabetes Clinical Pharmacology & Therapeutics. 77: P56-P56. DOI: 10.1016/j.clpt.2004.12.104 |
0.033 |
|
| 2015 |
Chen C, Chen Y, He Y. [Observation of 68 cases of auricular pseudo cyst treated with suture and compression bandage]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Chinese Journal of Otorhinolaryngology Head and Neck Surgery. 50: 1033-4. PMID 26888137 |
0.032 |
|
| 2023 |
Wang J, Shen S, Yan B, He Y, Zhang G, Shan C, Yang Q, Qin L, Duan Z, Jiang L, Wang X, Wei X, Wang C, Chen R, Zhang L. Individual exposure of ambient particulate matters and eosinophilic chronic rhinosinusitis with nasal Polyps: Dose-Response, mediation effects and recurrence prediction. Environment International. 177: 108031. PMID 37327504 DOI: 10.1016/j.envint.2023.108031 |
0.032 |
|
| 2005 |
HE Y, HOROWITZ A, WATSON C, FOLEY J, SALLAS W, LIGUEROSSAYLAN M. Lack of effect of LAF237 on C-peptide clearance in patients with type 2 diabetes Clinical Pharmacology & Therapeutics. 77: P56-P56. DOI: 10.1016/j.clpt.2004.12.105 |
0.025 |
|
| 2006 |
HE Y, SABO R, PICARD F, WANG Y, CAMPESTRINI J, HERRON J, LIGUEROSSAYLAN M. PIII-16Lack of pharmacokinetic interaction between Vildagliptin and Metformin in patients with type 2 diabetes Clinical Pharmacology & Therapeutics. 79: P62-P62. DOI: 10.1016/j.clpt.2005.12.224 |
0.025 |
|
| 2006 |
HE Y, SABO R, BALEZ S, WANG Y, CAMPESTRINI J, MARION A, LIGUEROSSAYLAN M. PII-12Absolute bioavailability of vildagliptin in healthy subjects Clinical Pharmacology & Therapeutics. 79: P38-P38. DOI: 10.1016/j.clpt.2005.12.137 |
0.017 |
|
| 2005 |
Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Current Medical Research and Opinion. 21: 1317-27. PMID 16083542 DOI: 10.1185/030079905X56565 |
0.012 |
|
| 2023 |
Peng J, He Y, Zheng L, Wang S, Cheng W. Analysis of image motion for optical remote sensing satellites staring imaging with area-array detectors. Applied Optics. 62: 2470-2478. PMID 37132794 DOI: 10.1364/AO.483974 |
0.01 |
|
| 2006 |
HE Y, SABO R, WANG Y, CAMPESTRINI J, RIVERE G, SALTZMAN M, LIGUEROSSAYLAN M. PIII-19The influence of age, gender and BMI on the pharmacokinetics and pharmacodynamics of vildagliptin Clinical Pharmacology & Therapeutics. 79: P63-P63. DOI: 10.1016/j.clpt.2005.12.227 |
0.01 |
|
| Hide low-probability matches. |